Precision BioSciences Defends its DNE Technology in Infringement Lawsuit
Precision BioSciences, Inc. is fighting a patent infringement lawsuit filed by by Cellectis SA, a French company focused on genome engineering.
Precision’s management described Cellectis’ allegations as unfounded and stated that no such infringement has occurred.
“Precision has reviewed Cellectis’ patent claims. It is clear that our next-generation genome engineering technology is demonstrably distinct from the dated technology covered by Cellectis’ patents,” said Matthew Kane, Precision's chief executive officer. “This lawsuit appears to stem from a fundamental misunderstanding of Precision’s DNE technology and how it is employed.”
The proprietary technology developed by Precision, called Directed Nuclease EditorTM (DNE), enables the production of genome editing enzymes that can be customized to modify essentially any gene in plant or animal cells.
Kane denies any wrongdoing and plans to vigorously defend the company's cutting-edge DNE technology being used for therapeutic, agricultural, and diagnostic applications. Precision has engaged WilmerHale, a law firm with one of the nation’s premier intellectual property litigation groups.
Copyright 2012 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
